The objective of this study is to characterize the natural history of phenylketonuria (PKU) due to phenylalanine hydroxylase (PAH) deficiency in adults through prospective collection of clinical, cognitive, and quality of life assessments.
Phenylalanine hydroxylase (PAH) deficiency is a rare disease caused by an inborn error of metabolism. If left untreated, PAH deficiency results in progressive, irreversible neurological impairment during infancy and early childhood. This study is designed to collect information about important PKU-related symptoms and tests to characterize the natural history of PKU due to PAH deficiency in a selected sample of adults. No new investigational treatment will be administered to participating patients.
Study Type
OBSERVATIONAL
Enrollment
7
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Children's Hospital of Orange County
Orange, California, United States
University of South Florida
Tampa, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Plasma phenylalanine (Phe) concentrations
Change in plasma Phe concentrations throughout study duration
Time frame: Baseline to Week 52
Plasma tyrosine (Tyr) concentrations
Change in plasma Tyr concentrations throughout study duration
Time frame: Baseline to Week 52
Quality of life (QOL), as assessed using the PKU-QOL questionnaire measures
Changes in PKU-QOL
Time frame: Baseline to Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Community Health Clinic
Topeka, Indiana, United States
University of Pittsburgh Medical Center- CHOP
Pittsburgh, Pennsylvania, United States
UT Southwestern Medical Center
Dallas, Texas, United States
University of Utah Health
Salt Lake City, Utah, United States